Matches in SemOpenAlex for { <https://semopenalex.org/work/W1569774431> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W1569774431 endingPage "91" @default.
- W1569774431 startingPage "681" @default.
- W1569774431 abstract "Amsterdam Molecular Therapeutics BV is developing alipogene tiparvovec (Glybera, AMT-011, AAV1-LPLS447X), a Ser(447)X variant of the human lipoprotein lipase (LPL) gene (LPLSer(447)X) in an adeno-associated virus vector, as a potential intramuscular gene therapy for the treatment of LPL deficiency. Familial LPL deficiency is a rare, autosomal-recessive disorder of lipoprotein metabolism that is characterized by severe hypertriglyceridemia with episodes of abdominal pain, acute pancreatitis and eruptive cutaneous xanthomatosis. The lack of functional LPL in patients with LPL deficiency causes an accumulation of triglyceride (TG)-rich lipoproteins in the plasma. The LPLSer(447)X variant is associated with decreased levels of plasma TGs and increased HDL cholesterol concentrations compared with wild-type LPL. Preclinical studies evaluating alipogene tiparvovec in a mouse model of LPL deficiency demonstrated a long-term, dose-dependent correction of the lipid abnormalities. The first clinical trials in patients with LPL deficiency appear promising, with a significant decrease in the levels of plasma TGs observed in the first 3 months following the administration of alipogene tiparvovec, and an increase in local LPL activity and protein levels observed after 6 months. In addition, a decrease in pancreatitis frequency was observed during a 3-year follow-up period. At the time of publication, a phase II/III trial in patients with LPL deficiency, being conducted to further support the submission of an MAA to the EMEA for alipogene tiparvovec, was ongoing. The compound is also under investigation for the treatment of type V hyperlipoproteinemia, Syndrome X and non-alcoholic steatohepatitis." @default.
- W1569774431 created "2016-06-24" @default.
- W1569774431 creator A5006036283 @default.
- W1569774431 creator A5066973981 @default.
- W1569774431 date "2009-12-01" @default.
- W1569774431 modified "2023-09-25" @default.
- W1569774431 title "Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency." @default.
- W1569774431 cites W1581644589 @default.
- W1569774431 cites W1925248176 @default.
- W1569774431 cites W1982040758 @default.
- W1569774431 cites W2022676255 @default.
- W1569774431 cites W2073214058 @default.
- W1569774431 cites W2149993680 @default.
- W1569774431 cites W2150638562 @default.
- W1569774431 cites W2402297639 @default.
- W1569774431 cites W3216297003 @default.
- W1569774431 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20072945" @default.
- W1569774431 hasPublicationYear "2009" @default.
- W1569774431 type Work @default.
- W1569774431 sameAs 1569774431 @default.
- W1569774431 citedByCount "25" @default.
- W1569774431 countsByYear W15697744312012 @default.
- W1569774431 countsByYear W15697744312013 @default.
- W1569774431 countsByYear W15697744312014 @default.
- W1569774431 countsByYear W15697744312015 @default.
- W1569774431 countsByYear W15697744312016 @default.
- W1569774431 countsByYear W15697744312017 @default.
- W1569774431 countsByYear W15697744312018 @default.
- W1569774431 countsByYear W15697744312019 @default.
- W1569774431 countsByYear W15697744312021 @default.
- W1569774431 countsByYear W15697744312022 @default.
- W1569774431 countsByYear W15697744312023 @default.
- W1569774431 crossrefType "journal-article" @default.
- W1569774431 hasAuthorship W1569774431A5006036283 @default.
- W1569774431 hasAuthorship W1569774431A5066973981 @default.
- W1569774431 hasConcept C126322002 @default.
- W1569774431 hasConcept C134018914 @default.
- W1569774431 hasConcept C171089720 @default.
- W1569774431 hasConcept C2775967933 @default.
- W1569774431 hasConcept C2776670229 @default.
- W1569774431 hasConcept C2776919658 @default.
- W1569774431 hasConcept C2778163477 @default.
- W1569774431 hasConcept C2778913445 @default.
- W1569774431 hasConcept C2780072125 @default.
- W1569774431 hasConcept C71924100 @default.
- W1569774431 hasConcept C94879076 @default.
- W1569774431 hasConceptScore W1569774431C126322002 @default.
- W1569774431 hasConceptScore W1569774431C134018914 @default.
- W1569774431 hasConceptScore W1569774431C171089720 @default.
- W1569774431 hasConceptScore W1569774431C2775967933 @default.
- W1569774431 hasConceptScore W1569774431C2776670229 @default.
- W1569774431 hasConceptScore W1569774431C2776919658 @default.
- W1569774431 hasConceptScore W1569774431C2778163477 @default.
- W1569774431 hasConceptScore W1569774431C2778913445 @default.
- W1569774431 hasConceptScore W1569774431C2780072125 @default.
- W1569774431 hasConceptScore W1569774431C71924100 @default.
- W1569774431 hasConceptScore W1569774431C94879076 @default.
- W1569774431 hasIssue "6" @default.
- W1569774431 hasLocation W15697744311 @default.
- W1569774431 hasOpenAccess W1569774431 @default.
- W1569774431 hasPrimaryLocation W15697744311 @default.
- W1569774431 hasRelatedWork W1512675439 @default.
- W1569774431 hasRelatedWork W1999361299 @default.
- W1569774431 hasRelatedWork W2026404846 @default.
- W1569774431 hasRelatedWork W2042889415 @default.
- W1569774431 hasRelatedWork W2065426685 @default.
- W1569774431 hasRelatedWork W2084294194 @default.
- W1569774431 hasRelatedWork W2141238176 @default.
- W1569774431 hasRelatedWork W2277158070 @default.
- W1569774431 hasRelatedWork W2293951605 @default.
- W1569774431 hasRelatedWork W2340558421 @default.
- W1569774431 hasVolume "11" @default.
- W1569774431 isParatext "false" @default.
- W1569774431 isRetracted "false" @default.
- W1569774431 magId "1569774431" @default.
- W1569774431 workType "article" @default.